Sugi Predict

Sugi Predict / Compounds / SCHEMBL23219225

SCHEMBL23219225

SCHEMBL23219225

CCOC(=O)Cc1ccc(OC)cc1OCc1coc2ccc(-c3ccnc(CN[S+]([O-])C(C)(C)C)c3)cc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.38
▸ MAPT P10636 5/20 0.37
▸ TSHR P16473 2/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ L3MBTL1 Q9Y468 3/20 0.35
▸ MTNR1A P48039 5/20 0.34
▸ THRB P10828 1/20 0.34
▸ MEN1 O00255 3/20 0.34
▸ KMT2A Q03164 3/20 0.34
▸ MTNR1B P49286 2/20 0.34
▸ LMNA P02545 2/20 0.34
▸ NQO2 P16083 1/20 0.34
▸ USP2 O75604 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ HIF1A Q16665 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218337 0.91 POLB (0.38) POLBMAPTTSHRMAPK1L3MBTL1
SCHEMBL23218929 0.90 MAPT (0.36) POLBMAPTTSHRMAPK1THRB
SCHEMBL23219218 0.89 POLB (0.36) POLBMAPTTSHRMAPK1L3MBTL1
SCHEMBL23229167 0.86 MAPT (0.38) POLBMAPTTSHRMAPK1L3MBTL1
SCHEMBL23656685 0.80 EPHX2 (0.32) MAPTTSHRTHRBCYP1A2CYP3A4
SCHEMBL29634131 0.80 EPHX2 (0.32) MAPTTSHRTHRBCYP1A2CYP3A4
SCHEMBL21562066 0.80 EPHX2 (0.32) MAPTTSHRTHRBCYP1A2CYP3A4
SCHEMBL24200302 0.80 EPHX2 (0.32) MAPTTSHRTHRBCYP1A2CYP3A4
SCHEMBL23219090 0.79 TBXAS1 (0.34) POLBMAPTMEN1KMT2A
SCHEMBL28736233 0.79 POLB (0.36) POLBMAPTTSHRMAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY ACADIA PHARMACEUTICALS INC. 2016-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY SLC6A4, HTR4, GPR34 POLB 1545/4885MAPT 234/4885TSHR 847/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB POLB 3530/4885MAPT 4793/4885TSHR 1199/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB POLB 2655/4885MAPT 3561/4885TSHR 3148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.